Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 1669, March 15, 2008. doi: 10.1158/1078-0432.CCR-07-0990
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weichert, W.
Right arrow Articles by Denkert, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weichert, W.
Right arrow Articles by Denkert, C.

Human Cancer Biology

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

Wilko Weichert1, Annika Röske1, Silvia Niesporek1, Aurelia Noske1, Ann-Christin Buckendahl1, Manfred Dietel1, Volker Gekeler2, Markus Boehm2, Thomas Beckers2 and Carsten Denkert1

Authors' Affiliations: 1 Institut für Pathologie, Charité Universitätsmedizin, Berlin, Germany and 2 Therapeutic Area Oncology, Altana Pharma AG, Konstanz, Germany

Requests for reprints: Wilko Weichert, Institut für Pathologie, Charité Universitätsmedizin, Schumannstraße 20/21, 10117 Berlin, Germany. Phone: 49-304-50536006; Fax: 49-304-50536922; E-mail: wilko.weichert{at}charite.de.

Purpose: Recently, several studies reported a strong functional link between histone deacetylases (HDAC) and the development of tumors of the large intestine. However, despite the importance of these molecules, comparably little is known on expression patterns and functions of specific HDAC isoforms in colorectal cancer.

Experimental Design: We characterized class I HDAC isoform expression patterns in a cohort of 140 colorectal carcinomas by immunohistochemistry. In addition, effects of HDAC inhibition by valproic acid and suberoylanilide hydroxamic acid, and specific HDAC isoform knockdown by short interfering RNA, were investigated in a cell culture model.

Results: We found class I HDACs highly expressed in a subset of colorectal carcinomas with positivity for HDAC1 in 36.4%, HDAC2 in 57.9%, and HDAC3 in 72.9% of cases. Expression was significantly enhanced in strongly proliferating (P = 0.002), dedifferentiated (P = 0.022) tumors. High HDAC expression levels implicated significantly reduced patient survival (P = 0.001), with HDAC2 expression being an independent survival prognosticator (hazard ratio, 2.6; P = 0.03). Short interfering RNA–based inhibition of HDAC1 and HDAC2 but not HDAC3 suppressed growth of colon cancer cells in vitro, although to a lesser extent than chemical HDAC inhibitors did.

Conclusions: The strong prognostic impact of HDAC isoforms in colorectal cancer, the interactions of HDACs with tumor cell proliferation and differentiation in vivo, and our finding that HDACs are differentially expressed in colorectal tumors suggest that the evaluation of HDAC expression in clinical trials for HDAC inhibitors might help to identify a patient subgroup who will exceptionally profit from such a treatment.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Ogino, K. Nosho, N. Irahara, S. Kure, K. Shima, Y. Baba, S. Toyoda, L. Chen, E. L. Giovannucci, J. A. Meyerhardt, et al.
A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases
Clin. Cancer Res., July 1, 2009; 15(13): 4431 - 4438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. S. Schrump
Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Ellis, P. W. Atadja, and R. W. Johnstone
Epigenetics in cancer: Targeting chromatin modifications
Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Nosho, K. Shima, N. Irahara, S. Kure, Y. Baba, G. J. Kirkner, L. Chen, S. Gokhale, A. Hazra, D. Spiegelman, et al.
DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer
Clin. Cancer Res., June 1, 2009; 15(11): 3663 - 3671.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery, and E. N. Olson
Genetic dissection of histone deacetylase requirement in tumor cells
PNAS, May 12, 2009; 106(19): 7751 - 7755.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Suzuki, Y.-Y. Chen, G. K. Scott, S. DeVries, K. Chin, C. C. Benz, F. M. Waldman, and E. S. Hwang
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression
Clin. Cancer Res., May 1, 2009; 15(9): 3163 - 3171.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.